Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Stock Competitors & Peer Comparison

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, REGN has a market cap of 82.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while REGN trades at $805.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas REGN's P/E ratio is 17.64. In terms of profitability, VRTX's ROE is +0.23%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VRTX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check REGN's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, MRNA has a market cap of 79.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while MRNA trades at $200.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas MRNA's P/E ratio is -24.55. In terms of profitability, VRTX's ROE is +0.23%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, VRTX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check MRNA's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VRTX's ROE is +0.23%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, VRTX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check VRNA's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ARGX has a market cap of 54.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ARGX trades at $873.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ARGX's P/E ratio is 31.50. In terms of profitability, VRTX's ROE is +0.23%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, VRTX is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ARGX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRTX's ROE is +0.23%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRTX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check SGEN's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ONC has a market cap of 40.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ONC trades at $377.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ONC's P/E ratio is 66.48. In terms of profitability, VRTX's ROE is +0.23%, compared to ONC's ROE of +0.14%. Regarding short-term risk, VRTX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ONC's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, RVMDW has a market cap of 40.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while RVMDW trades at $9.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas RVMDW's P/E ratio is -1.06. In terms of profitability, VRTX's ROE is +0.23%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, VRTX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check RVMDW's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, RVMD has a market cap of 40.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while RVMD trades at $186.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas RVMD's P/E ratio is -21.22. In terms of profitability, VRTX's ROE is +0.23%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, VRTX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check RVMD's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ALNY has a market cap of 30B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ALNY trades at $224.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ALNY's P/E ratio is 40.37. In terms of profitability, VRTX's ROE is +0.23%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, VRTX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ALNY's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, GMAB has a market cap of 26.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while GMAB trades at $43.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas GMAB's P/E ratio is 33.00. In terms of profitability, VRTX's ROE is +0.23%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, VRTX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check GMAB's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ROIV has a market cap of 26.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ROIV trades at $36.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ROIV's P/E ratio is -34.72. In terms of profitability, VRTX's ROE is +0.23%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, VRTX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ROIV's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while UTHR trades at $587.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas UTHR's P/E ratio is 21.02. In terms of profitability, VRTX's ROE is +0.23%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, VRTX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check UTHR's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, INCY has a market cap of 23.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while INCY trades at $115.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas INCY's P/E ratio is 15.55. In terms of profitability, VRTX's ROE is +0.23%, compared to INCY's ROE of +0.30%. Regarding short-term risk, VRTX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check INCY's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, BNTX has a market cap of 22.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while BNTX trades at $88.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas BNTX's P/E ratio is -11.43. In terms of profitability, VRTX's ROE is +0.23%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, VRTX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check BNTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, INSM has a market cap of 20.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while INSM trades at $93.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas INSM's P/E ratio is -22.72. In terms of profitability, VRTX's ROE is +0.23%, compared to INSM's ROE of -1.11%. Regarding short-term risk, VRTX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check INSM's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRTX's ROE is +0.23%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, VRTX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check BGNE's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRTX's ROE is +0.23%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, VRTX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check DNA-WT's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, EXEL has a market cap of 16.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while EXEL trades at $64.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas EXEL's P/E ratio is 18.44. In terms of profitability, VRTX's ROE is +0.23%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, VRTX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check EXEL's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ASND has a market cap of 15.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ASND trades at $243.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ASND's P/E ratio is -100.57. In terms of profitability, VRTX's ROE is +0.23%, compared to ASND's ROE of +1.90%. Regarding short-term risk, VRTX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ASND's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, NBIX has a market cap of 14.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while NBIX trades at $142.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas NBIX's P/E ratio is 20.62. In terms of profitability, VRTX's ROE is +0.23%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, VRTX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check NBIX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, HALO has a market cap of 14.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while HALO trades at $125.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas HALO's P/E ratio is 23.44. In terms of profitability, VRTX's ROE is +0.23%, compared to HALO's ROE of +1.81%. Regarding short-term risk, VRTX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check HALO's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, JAZZ has a market cap of 13.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while JAZZ trades at $214.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas JAZZ's P/E ratio is 7.98. In terms of profitability, VRTX's ROE is +0.23%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, VRTX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check JAZZ's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while BBIO trades at $68.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas BBIO's P/E ratio is -18.33. In terms of profitability, VRTX's ROE is +0.23%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, VRTX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check BBIO's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRTX's ROE is +0.23%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRTX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check KRTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, SMMT has a market cap of 12.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while SMMT trades at $15.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas SMMT's P/E ratio is -13.81. In terms of profitability, VRTX's ROE is +0.23%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, VRTX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check SMMT's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while TECH trades at $72.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas TECH's P/E ratio is 37.40. In terms of profitability, VRTX's ROE is +0.23%, compared to TECH's ROE of +0.09%. Regarding short-term risk, VRTX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check TECH's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VRTX's ROE is +0.23%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, VRTX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check RNAM's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while BMRN trades at $55.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas BMRN's P/E ratio is 26.90. In terms of profitability, VRTX's ROE is +0.23%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, VRTX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check BMRN's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, MDGL has a market cap of 10B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while MDGL trades at $434.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas MDGL's P/E ratio is -33.92. In terms of profitability, VRTX's ROE is +0.23%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, VRTX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check MDGL's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRTX's ROE is +0.23%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRTX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check RXDX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, PCVX has a market cap of 9.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while PCVX trades at $60.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas PCVX's P/E ratio is -7.92. In terms of profitability, VRTX's ROE is +0.23%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, VRTX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PCVX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, TXG has a market cap of 9.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while TXG trades at $71.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas TXG's P/E ratio is -121.02. In terms of profitability, VRTX's ROE is +0.23%, compared to TXG's ROE of -0.09%. Regarding short-term risk, VRTX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TXG's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while KRYS trades at $311.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas KRYS's P/E ratio is 39.04. In terms of profitability, VRTX's ROE is +0.23%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VRTX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check KRYS's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, TWST has a market cap of 9.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while TWST trades at $139.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas TWST's P/E ratio is -62.99. In terms of profitability, VRTX's ROE is +0.23%, compared to TWST's ROE of -0.30%. Regarding short-term risk, VRTX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TWST's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas NUVL's P/E ratio is -21.79. In terms of profitability, VRTX's ROE is +0.23%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VRTX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check NUVL's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while KYMR trades at $110.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas KYMR's P/E ratio is -34.61. In terms of profitability, VRTX's ROE is +0.23%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, VRTX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check KYMR's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CAI has a market cap of 9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CAI trades at $32.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CAI's P/E ratio is 89.91. In terms of profitability, VRTX's ROE is +0.23%, compared to CAI's ROE of +0.19%. Regarding short-term risk, VRTX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CAI's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CRNX's P/E ratio is -16.86. In terms of profitability, VRTX's ROE is +0.23%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VRTX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CRNX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while PTGX trades at $138.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas PTGX's P/E ratio is 134.40. In terms of profitability, VRTX's ROE is +0.23%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, VRTX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PTGX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRTX's ROE is +0.23%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VRTX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check IMGN's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, IBRX has a market cap of 8.7B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while IBRX trades at $8.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas IBRX's P/E ratio is -8.47. In terms of profitability, VRTX's ROE is +0.23%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, VRTX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check IBRX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CYTK has a market cap of 8.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CYTK trades at $61.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CYTK's P/E ratio is -8.48. In terms of profitability, VRTX's ROE is +0.23%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, VRTX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CYTK's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas APGE's P/E ratio is -31.19. In terms of profitability, VRTX's ROE is +0.23%, compared to APGE's ROE of -0.30%. Regarding short-term risk, VRTX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check APGE's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VRTX's ROE is +0.23%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, VRTX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check BPMC's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, SYRE has a market cap of 8.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while SYRE trades at $90.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas SYRE's P/E ratio is -46.32. In terms of profitability, VRTX's ROE is +0.23%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, VRTX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check SYRE's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while TGTX trades at $54.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas TGTX's P/E ratio is 19.63. In terms of profitability, VRTX's ROE is +0.23%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, VRTX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TGTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ARWR has a market cap of 8.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ARWR trades at $58.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ARWR's P/E ratio is -25.79. In terms of profitability, VRTX's ROE is +0.23%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, VRTX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ARWR's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRTX's ROE is +0.23%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VRTX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CERE's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ABVX trades at $88.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ABVX's P/E ratio is -14.42. In terms of profitability, VRTX's ROE is +0.23%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, VRTX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ABVX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, AXSM has a market cap of 7.6B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while AXSM trades at $145.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas AXSM's P/E ratio is -37.87. In terms of profitability, VRTX's ROE is +0.23%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, VRTX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check AXSM's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VRTX's ROE is +0.23%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, VRTX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check MTSR's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, IONS has a market cap of 7.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while IONS trades at $42.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas IONS's P/E ratio is -13.13. In terms of profitability, VRTX's ROE is +0.23%, compared to IONS's ROE of -1.11%. Regarding short-term risk, VRTX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check IONS's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while PRAX trades at $252.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas PRAX's P/E ratio is -19.56. In terms of profitability, VRTX's ROE is +0.23%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, VRTX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PRAX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VRTX's ROE is +0.23%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, VRTX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check MRUS's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VRTX's ROE is +0.23%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, VRTX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ACLX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRTX's ROE is +0.23%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRTX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check RETA's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, IOVA has a market cap of 6.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while IOVA trades at $14.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas IOVA's P/E ratio is -19.30. In terms of profitability, VRTX's ROE is +0.23%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, VRTX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check IOVA's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VRTX's ROE is +0.23%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VRTX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CNTA's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while RYTM trades at $89.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas RYTM's P/E ratio is -28.70. In terms of profitability, VRTX's ROE is +0.23%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, VRTX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check RYTM's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas TERN's P/E ratio is -51.41. In terms of profitability, VRTX's ROE is +0.23%, compared to TERN's ROE of -0.14%. Regarding short-term risk, VRTX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check TERN's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while LGND trades at $303.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas LGND's P/E ratio is 33.32. In terms of profitability, VRTX's ROE is +0.23%, compared to LGND's ROE of +0.20%. Regarding short-term risk, VRTX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check LGND's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while BLTE trades at $147.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas BLTE's P/E ratio is -78.79. In terms of profitability, VRTX's ROE is +0.23%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, VRTX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check BLTE's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while IMVT trades at $28.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas IMVT's P/E ratio is -10.07. In terms of profitability, VRTX's ROE is +0.23%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, VRTX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check IMVT's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while MANE trades at $138.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas MANE's P/E ratio is -44.30. In terms of profitability, VRTX's ROE is +0.23%, compared to MANE's ROE of -0.38%. Regarding short-term risk, VRTX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check MANE's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VRTX's ROE is +0.23%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, VRTX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CDTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRTX's ROE is +0.23%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRTX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ABCM's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRTX's ROE is +0.23%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRTX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ISEE's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, KOD has a market cap of 5.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while KOD trades at $87.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas KOD's P/E ratio is -21.01. In terms of profitability, VRTX's ROE is +0.23%, compared to KOD's ROE of -2.73%. Regarding short-term risk, VRTX is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check KOD's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CGON trades at $61.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CGON's P/E ratio is -22.94. In terms of profitability, VRTX's ROE is +0.23%, compared to CGON's ROE of -0.25%. Regarding short-term risk, VRTX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CGON's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while COGT trades at $31.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas COGT's P/E ratio is -14.79. In terms of profitability, VRTX's ROE is +0.23%, compared to COGT's ROE of -0.73%. Regarding short-term risk, VRTX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check COGT's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ORKA has a market cap of 5.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ORKA trades at $80.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ORKA's P/E ratio is -41.31. In terms of profitability, VRTX's ROE is +0.23%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, VRTX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ORKA's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas APLS's P/E ratio is 38.35. In terms of profitability, VRTX's ROE is +0.23%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VRTX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check APLS's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, MIRM has a market cap of 5.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while MIRM trades at $80.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas MIRM's P/E ratio is -5.53. In terms of profitability, VRTX's ROE is +0.23%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, VRTX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check MIRM's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, PTCT has a market cap of 5.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while PTCT trades at $60.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas PTCT's P/E ratio is -26.00. In terms of profitability, VRTX's ROE is +0.23%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, VRTX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PTCT's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, SRRK has a market cap of 5.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while SRRK trades at $41.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas SRRK's P/E ratio is -12.03. In terms of profitability, VRTX's ROE is +0.23%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, VRTX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check SRRK's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ERAS trades at $14.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ERAS's P/E ratio is -15.47. In terms of profitability, VRTX's ROE is +0.23%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, VRTX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ERAS's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while DFTX trades at $35.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas DFTX's P/E ratio is N/A. In terms of profitability, VRTX's ROE is +0.23%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, VRTX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check DFTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CRSP trades at $49.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CRSP's P/E ratio is -10.38. In terms of profitability, VRTX's ROE is +0.23%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, VRTX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CRSP's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, TVTX has a market cap of 4.7B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while TVTX trades at $50.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas TVTX's P/E ratio is -111.22. In terms of profitability, VRTX's ROE is +0.23%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, VRTX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TVTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VRTX's ROE is +0.23%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, VRTX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check FOLD's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VRTX's ROE is +0.23%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, VRTX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check AKRO's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRTX's ROE is +0.23%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VRTX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ALPN's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while DNTH trades at $76.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas DNTH's P/E ratio is -18.50. In terms of profitability, VRTX's ROE is +0.23%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, VRTX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check DNTH's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRTX's ROE is +0.23%, compared to OPT's ROE of +1.18%. Regarding short-term risk, VRTX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check OPT's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas PRTC's P/E ratio is -3.78. In terms of profitability, VRTX's ROE is +0.23%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, VRTX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PRTC's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while EWTX trades at $39.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas EWTX's P/E ratio is -21.25. In terms of profitability, VRTX's ROE is +0.23%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, VRTX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check EWTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRTX's ROE is +0.23%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRTX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check MRTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ADPT trades at $25.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ADPT's P/E ratio is -62.22. In terms of profitability, VRTX's ROE is +0.23%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, VRTX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ADPT's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while RLAY trades at $18.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas RLAY's P/E ratio is -11.58. In terms of profitability, VRTX's ROE is +0.23%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, VRTX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check RLAY's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while TNGX trades at $23.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas TNGX's P/E ratio is -28.12. In terms of profitability, VRTX's ROE is +0.23%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, VRTX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TNGX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ARQT has a market cap of 3.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ARQT trades at $31.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ARQT's P/E ratio is 148.57. In terms of profitability, VRTX's ROE is +0.23%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, VRTX is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ARQT's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CPRX's P/E ratio is 17.49. In terms of profitability, VRTX's ROE is +0.23%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VRTX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CPRX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while ABCL trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas ABCL's P/E ratio is -21.89. In terms of profitability, VRTX's ROE is +0.23%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, VRTX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ABCL's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRTX's ROE is +0.23%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRTX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check RYZB's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VRTX's ROE is +0.23%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VRTX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CBAY's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while LEGN trades at $19.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas LEGN's P/E ratio is -28.34. In terms of profitability, VRTX's ROE is +0.23%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, VRTX is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check LEGN's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas SWTX's P/E ratio is -13.78. In terms of profitability, VRTX's ROE is +0.23%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, VRTX is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check SWTX's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, XENE has a market cap of 3.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while XENE trades at $35.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas XENE's P/E ratio is -7.52. In terms of profitability, VRTX's ROE is +0.23%, compared to XENE's ROE of -0.44%. Regarding short-term risk, VRTX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check XENE's competition here

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRTX stands at 132.8B. In comparison, AMLX has a market cap of 3.4B. Regarding current trading prices, VRTX is priced at $523.93 on the NASDAQ, while AMLX trades at $27.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRTX currently has a P/E ratio of 27.53, whereas AMLX's P/E ratio is -18.13. In terms of profitability, VRTX's ROE is +0.23%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, VRTX is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check AMLX's competition here